Source: Hana Biosciences, Inc.

Hana Biosciences Patent Issued for Menadione for the Prevention and Treatment of EGFR Inhibitor Cancer Therapy-Associated Rash

SOUTH SAN FRANCISCO, Calif., July 8, 2010 (GLOBE NEWSWIRE) -- Hana Biosciences, Inc. (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that it was issued U.S. patent number 7,745,494, which covers a method of using menadione topical lotion in treating...

admin

July 06, 2010 08:01 AM Eastern Daylight Time

Combination of Imprime PGG and Erbitux Doubles the Therapeutic Response in Colorectal Cancer Patients in Phase Ib/IIa Trial

Data Released at the European Society for Medical Oncology

BARCELONA, Spain--(BUSINESS WIRE)--The combination of Biothera’s experimental drug Imprime PGG® and Erbitux® (cetuximab) doubled the historical overall response rate and the time to progression of second- and third-line metastatic...

admin

Cancer specialists in Australia are calling for a national policy on genetic testing of cancer patients in public and private hospitals to identify who can receive particular drugs that work only in the presence or absence of a particular gene.

The call comes as the Pharmaceutical Benefits Advisory Committee decides this week whether or not to recommend a subsidy for Erbitux, a Merck Serono drug for treating bowel cancer. The drug can shrink tumours depending on a patient's gene....

admin

Data Published in Proceedings of National Academy of Sciences Highlights Potential of Micromet's BiTE Antibody Platform

BETHESDA, Md., June 29 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), today announced the publication of pre-clinical data in the Proceedings of the National Academy of Sciences (PNAS), demonstrating the potency of new product candidates based on the Company's proprietary BiTE® antibody technology. BiTE antibodies are a new class of agents designed to harness...

admin

By Tom Randall

June 6 (Bloomberg) -- Eli Lilly & Co. and Merck KGaA’s Erbitux, approved for advanced colon cancer, failed to slow tumors in a study designed to expand the medicine’s use to patients whose disease is in an earlier stage.

Erbitux, used to treat aggressive colorectal tumors that have reached other areas of the body, didn’t help stop the spread when added to chemotherapy, according to a study reported today at the American Society of Clinical Oncology meeting...

admin